Latest United States News

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Peak Processing Limited’s FY26 results reveal a doubling loss from continuing operations to $10 million amid a $4.35 million impairment, offset partially by a $2.5 million profit from discontinued operations. The company completed an operational reset and posted its first positive EBITDA quarter in June 2026.

L1 Gold Fund Limited (ASX:LGF) has launched a retail entitlement offer aiming to raise up to $261.7 million by issuing one new share for every three held, priced at $2.25 each. This follows a $254.9 million institutional placement and entitlement offer completed earlier in August.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Swift TV Ltd advanced its commercial rollout with 7,190 devices sold and secured key technology certifications in FY26, while navigating a 22% revenue decline due to legacy contract wind-downs. The company delivered positive EBITDA and raised $2.3 million to fund growth initiatives.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.